Home » Stocks » CODX

Co-Diagnostics, Inc. (CODX)

Stock Price: $7.16 USD -0.15 (-2.05%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $7.66 +0.50 (6.98%) May 13, 7:57 PM
Market Cap 205.25M
Revenue (ttm) 74.55M
Net Income (ttm) 42.48M
Shares Out 26.72M
EPS (ttm) 1.52
PE Ratio 4.71
Forward PE 10.41
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $7.16
Previous Close $7.31
Change ($) -0.15
Change (%) -2.05%
Day's Open 7.40
Day's Range 7.01 - 7.55
Day's Volume 1,094,746
52-Week Range 7.01 - 30.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 30.00% and 2.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 hours ago - Zacks Investment Research

Shares of Co-Diagnostics (NASDAQ:CODX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 620.00% year over year to $0.26, which b...

6 hours ago - Benzinga

Co-Diagnostics Inc (NASDAQ:CODX) reported that it earned a first-quarter net profit -- versus a loss last year -- on strong sales of its Logix Smart COVID-19 Test. For the quarter ended March 31, the co...

6 hours ago - Proactive Investors

CoDiagnostics, Inc. (CODX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

SALT LAKE CITY, May 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, annou...

1 week ago - PRNewsWire

SALT LAKE CITY, April 29, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tes...

2 weeks ago - PRNewsWire

Co-Diagnostics Inc (NASDAQ:CODX) has noted that its Indian manufacturing facility, CoSara Diagnostics Pvt Ltd, has garnered media attention for its actions to provide much-needed coronavirus (COVID-19) ...

2 weeks ago - Proactive Investors

SALT LAKE CITY, April 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tes...

2 weeks ago - PRNewsWire

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others...

Other stocks mentioned: BDSI, KMDA, SURF, VMD
3 weeks ago - GuruFocus

Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company with a patented platform for the development of diagnostic tests, has revealed that its Logix Smart COVID-19 Test Kit was used by Austra...

3 weeks ago - Proactive Investors

SALT LAKE CITY, April 20, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced to...

3 weeks ago - PRNewsWire

CODX stock rose on the pandemic, but its prospects moving forward look bleak with a sales strategy that is suspect at best. The post If You Rode the Co-Diagnostics Stock Pandemic Highs, It's Time to Bai...

1 month ago - InvestorPlace

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy...

1 month ago - Proactive Investors

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan told Yahoo! Finance that “we believe COVID-19 will be here till the end of time” -- and that means individuals and organizations will need quick and easy...

1 month ago - Proactive Investors

SALT LAKE CITY, March 31, 2021 /PRNewswire/ -- The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, a...

1 month ago - PRNewsWire

Co-Diagnostics CEO discusses coronavirus testing: We believe robust testing is key to normalizing

YouTube video

coronavirustesting Yahoo Finance's Adam Shapiro and Seana Smith spoke with Co-Diagnostics CEO Dwight Egan about the company's outlook and the latest coronavirus testing methods.

1 month ago - Yahoo Finance

Analysts following this coronavirus stock have darkened their post-pandemic outlook.

1 month ago - The Motley Fool

The company's recent struggles on the stock market continue.

1 month ago - The Motley Fool

With the trading day about halfway over, the broad markets were pushing lower. The Dow Jones industrial average and S&P 500 were only down slightly to start the week, while the Nasdaq faced the worst of...

Other stocks mentioned: DOCU
1 month ago - 24/7 Wall Street

Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnost...

1 month ago - Proactive Investors

Develops products to detect infectious diseases in humans and animals Offers Logix Smart Coronavirus Disease detection test in US and globally Earned net income of $42.5 million in 2020 What Co-Diagnost...

1 month ago - Proactive Investors

Investors didn't like what they heard in the company's fourth-quarter update.

1 month ago - The Motley Fool

The company missed earnings expectations and hinted at slowing growth in 2021.

1 month ago - The Motley Fool

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -12.24% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Co-Diagnostics Inc (NASDAQ:CODX) announced Thursday that it earned a net income of $42.5 million in 2020 as its Logix Smart coronavirus (COVID-19) test drove record sales.  That's a huge turnaround for ...

1 month ago - Proactive Investors

Shares of Co-Diagnostics (NASDAQ:CODX) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 577.78% year over year to $0.43, which miss...

1 month ago - Benzinga

SALT LAKE CITY, March 25, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an...

1 month ago - PRNewsWire

CODX stock's true value isn't fully appreciated by the investing community, and this could provide a setup for an explosive move. The post Co-Diagnostics Stock Is an Out-and-Out Buy Before the Earnings ...

1 month ago - InvestorPlace

SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, an...

1 month ago - PRNewsWire

SALT LAKE CITY, March 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular d...

1 month ago - PRNewsWire

2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?

Other stocks mentioned: FLGT, JNJ, MRNA, NVAX
2 months ago - The Motley Fool

SALT LAKE CITY, March 10, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular d...

2 months ago - PRNewsWire

SALT LAKE CITY, March 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular di...

2 months ago - PRNewsWire

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

Other stocks mentioned: AGTC, ATOM, AYTU, CRTX, DVAX, SRNE
2 months ago - Investors Business Daily

Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. ...

2 months ago - Proactive Investors

Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. ...

2 months ago - Proactive Investors

Co-Diagnostics Inc (NASDAQ:CODX) has confirmed that its patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health p...

Other stocks mentioned: WBA
2 months ago - Proactive Investors

Its technology underpins a coronavirus test that's about to get much wider distribution.

2 months ago - The Motley Fool

Co-Diagnostics Inc (NASDAQ:CODX) patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer...

Other stocks mentioned: WBA
2 months ago - Proactive Investors

With the latter appointment, the company's founder moves into a more advisory role.

2 months ago - The Motley Fool

Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday the appointment of Brian Brown as the company's new chief financial officer (CFO). The company said Brown's previous experience includes CFO, vice pres...

2 months ago - Proactive Investors

SALT LAKE CITY, Feb. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced tod...

2 months ago - PRNewsWire

Co-Diagnostics Inc (NASDAQ:CODX) has said it will be presenting on direct saliva testing for coronavirus (COVID-19) at the 28th Annual International Molecular Medicine Tri-Conference, to be held virtual...

2 months ago - Proactive Investors

These companies have awesome upside potential, and they won't break the bank

Other stocks mentioned: TDS, TPH
3 months ago - The Motley Fool

The good news is that the end of the pandemic is in sight. The bad news is that it may never really be over.

Other stocks mentioned: FLGT
3 months ago - OTC PR Wire

This diagnostic specialist started off the year as a micro cap, but it roared ahead with its COVID-19 test.

3 months ago - The Motley Fool

SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular di...

3 months ago - PRNewsWire

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued...

Other stocks mentioned: BEEM, BLNK, CELH, CRDF, GNPX, GRWG, KIRK ...
3 months ago - Seeking Alpha

This business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.

3 months ago - The Motley Fool

Co-Diagnostics is well positioned to benefit from incremental fundamental momentum seen at the back end of 2020. The company's Covid-19 tests are differentiated by distinguishing between common cold and...

4 months ago - Seeking Alpha

About CODX

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also pro... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 12, 2017
CEO
Dwight Egan
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
CODX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Co-Diagnostics stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 221.23% from the latest price.

Price Target
$23.00
(221.23% upside)
Analyst Consensus: Buy